Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Pre-funded Warrants	Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Pre-funded Warrants	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at Dec. 31, 2023	$ (45,017)				$ 2,377			$ (47,394)
Balance, Shares at Dec. 31, 2023				1,362,481
Temporary Equity Balance at Dec. 31, 2023			$ 44,408
Temporary Equity Balance, Shares at Dec. 31, 2023			41,871,340
Issuance of Series B-2 redeemable convertible preferred stock			$ 1,591
Issuance of Series B-2 redeemable convertible preferred stock, Shares			1,280,000
Capital contributions - in-kind services - related party	60				60
Premium on issuance of convertible promissory notes	16,641				16,641
Issuance of common stock upon stock option exercises	3				3
Issuance of common stock upon stock option exercises, Shares				4,030
Repurchase of common stock in connection with the royalty agreement	(32)				(32)
Repurchase of common stock in connection with the royalty agreement, Shares				(10,080)
Stock-based compensation expense	895				895
Unrealized gain on marketable securities, net of tax	0
Vesting of restricted stock awards	1				1
Net loss	(69,167)							(69,167)
Balance at Dec. 31, 2024	(96,616)				19,945			(116,561)
Balance, Shares at Dec. 31, 2024				1,356,431
Temporary Equity Balance at Dec. 31, 2024	$ 45,999		$ 45,999
Temporary Equity Balance, Shares at Dec. 31, 2024	43,151,340		43,151,340
Premium on issuance of convertible promissory notes	$ 186				186
Issuance of Series B-2 redeemable convertible preferred stock upon conversion of convertible promissory notes in connection with the Merger			$ 3,695
Issuance of Series B-2 redeemable convertible preferred stock upon conversion of convertible promissory notes in connection with the Merger, Shares			794,499
Conversion of convertible promissory notes into common stock in connection with the Merger	20,799				20,799
Conversion of convertible promissory notes into common stock in connection with the Merger, Shares				3,418,839
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger			$ (49,694)
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger, Shares			(43,945,839)
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger	49,694			$ 1	49,693
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger, Shares				8,859,474
Recognition of AlloVir common stock outstanding at the closing of the Merger	104,990			$ 1	104,989
Recognition of AlloVir common stock outstanding at the closing of the Merger, Shares				5,067,674
Transaction costs related to the Merger	$ (5,357)				(5,357)
Issuance of common stock upon stock option exercises, Shares	0
Issuance of stock in private placement	$ 39,156	$ 7,458			39,156	$ 7,458
Issuance of stock in private placement, shares				4,200,000
Stock-based compensation expense	1,936				1,936
Unrealized gain on marketable securities, net of tax	6						$ 6
Net loss	(43,438)							(43,438)
Balance at Dec. 31, 2025	78,814			$ 2	$ 238,805		$ 6	$ (159,999)
Balance, Shares at Dec. 31, 2025				22,902,418
Temporary Equity Balance at Dec. 31, 2025	$ 0
Temporary Equity Balance, Shares at Dec. 31, 2025	0